Gentian Diagnostics AS (GENT) - Net Assets

Latest as of December 2025: Nkr204.96 Million NOK ≈ $21.57 Million USD

Based on the latest financial reports, Gentian Diagnostics AS (GENT) has net assets worth Nkr204.96 Million NOK (≈ $21.57 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr258.54 Million ≈ $27.21 Million USD) and total liabilities (Nkr53.58 Million ≈ $5.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Gentian Diagnostics AS to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Nkr204.96 Million
% of Total Assets	79.28%
Annual Growth Rate	49.69%
5-Year Change	17.28%
10-Year Change	77.39%
Growth Volatility	330.89

Gentian Diagnostics AS - Net Assets Trend (2013–2025)

This chart illustrates how Gentian Diagnostics AS's net assets have evolved over time, based on quarterly financial data. Also explore GENT current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Gentian Diagnostics AS (2013–2025)

The table below shows the annual net assets of Gentian Diagnostics AS from 2013 to 2025. For live valuation and market cap data, see Gentian Diagnostics AS (GENT) total market value.

Year	Net Assets	Change
2025-12-31	Nkr204.96 Million ≈ $21.57 Million	+5.62%
2024-12-31	Nkr194.05 Million ≈ $20.42 Million	+32.33%
2023-12-31	Nkr146.64 Million ≈ $15.43 Million	-4.89%
2022-12-31	Nkr154.17 Million ≈ $16.22 Million	-11.78%
2021-12-31	Nkr174.77 Million ≈ $18.39 Million	-10.18%
2020-12-31	Nkr194.58 Million ≈ $20.48 Million	-6.56%
2019-12-31	Nkr208.24 Million ≈ $21.91 Million	-15.31%
2018-12-31	Nkr245.87 Million ≈ $25.87 Million	+25.14%
2017-12-31	Nkr196.48 Million ≈ $20.67 Million	+70.05%
2016-12-31	Nkr115.54 Million ≈ $12.16 Million	+21.54%
2015-12-31	Nkr95.06 Million ≈ $10.00 Million	+1185.51%
2014-12-31	Nkr7.39 Million ≈ $778.15K	+356.50%
2013-12-31	Nkr1.62 Million ≈ $170.46K	--

Equity Component Analysis

This analysis shows how different components contribute to Gentian Diagnostics AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 11435534900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Other Components	Nkr319.57 Million	155.92%
Total Equity	Nkr204.96 Million	100.00%

Gentian Diagnostics AS Competitors by Market Cap

The table below lists competitors of Gentian Diagnostics AS ranked by their market capitalization.

Company	Market Cap
DK-Lok Corporation KQ:105740	$72.40 Million
Widodo Makmur Perkasa PT JK:WMPP	$72.40 Million
Siebert Financial Corp NASDAQ:SIEB	$72.47 Million
Metrofile JSE:MFL	$72.47 Million
Ozsu Balik Uretim A.S. IS:OZSUB	$72.35 Million
Pc Iletisim ve Medya Hizmetleri Sanayi Ticaret AS IS:PCILT	$72.35 Million
Woosu AMS Co.Ltd KQ:066590	$72.34 Million
GO Element Co. Ltd. KQ:311320	$72.32 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Gentian Diagnostics AS's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 194,050,000 to 204,957,000, a change of 10,907,000 (5.6%).
Net income of 13,256,000 contributed positively to equity growth.
Dividend payments of 6,169,000 reduced retained earnings.
Other comprehensive income increased equity by 890,000.
Other factors increased equity by 2,930,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Nkr13.26 Million	+6.47%
Dividends Paid	Nkr6.17 Million	-3.01%
Other Comprehensive Income	Nkr890.00K	+0.43%
Other Changes	Nkr2.93 Million	+1.43%
Total Change	Nkr-	5.62%

Book Value vs Market Value Analysis

This analysis compares Gentian Diagnostics AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.36x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 306.69x to 3.36x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2013-12-31	Nkr0.15	Nkr44.60	x
2014-12-31	Nkr0.66	Nkr44.60	x
2015-12-31	Nkr8.53	Nkr44.60	x
2016-12-31	Nkr10.37	Nkr44.60	x
2017-12-31	Nkr14.04	Nkr44.60	x
2018-12-31	Nkr15.97	Nkr44.60	x
2019-12-31	Nkr13.52	Nkr44.60	x
2020-12-31	Nkr12.63	Nkr44.60	x
2021-12-31	Nkr11.34	Nkr44.60	x
2022-12-31	Nkr10.00	Nkr44.60	x
2023-12-31	Nkr9.51	Nkr44.60	x
2024-12-31	Nkr12.31	Nkr44.60	x
2025-12-31	Nkr13.29	Nkr44.60	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Gentian Diagnostics AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 6.47%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7.51%
• Asset Turnover: 0.68x
• Equity Multiplier: 1.26x
Recent ROE (6.47%) is above the historical average (-3.65%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	53.95%	3.82%	1.62x	8.75x	Nkr712.00K
2014	-39.33%	-11.85%	1.27x	2.61x	Nkr-3.65 Million
2015	-3.39%	-12.59%	0.26x	1.05x	Nkr-12.73 Million
2016	-7.73%	-28.89%	0.25x	1.06x	Nkr-20.48 Million
2017	-7.72%	-43.36%	0.17x	1.04x	Nkr-34.82 Million
2018	-8.05%	-42.94%	0.18x	1.05x	Nkr-44.39 Million
2019	-19.14%	-83.12%	0.21x	1.09x	Nkr-60.68 Million
2020	-8.80%	-25.03%	0.29x	1.21x	Nkr-36.57 Million
2021	-14.19%	-29.83%	0.39x	1.21x	Nkr-42.27 Million
2022	-15.57%	-23.61%	0.54x	1.22x	Nkr-39.42 Million
2023	-7.26%	-7.82%	0.75x	1.23x	Nkr-25.31 Million
2024	23.34%	29.78%	0.66x	1.18x	Nkr25.89 Million
2025	6.47%	7.51%	0.68x	1.26x	Nkr-7.24 Million

Industry Comparison

This section compares Gentian Diagnostics AS's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $102,977,981
Average return on equity (ROE) among peers: 3.86%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Gentian Diagnostics AS (GENT)	Nkr204.96 Million	53.95%	0.26x	$72.38 Million
Lifecare AS (LIFE)	$55.25 Million	-31.63%	0.27x	$7.84 Million
Medistim ASA (MEDI)	$236.86 Million	29.68%	0.42x	$432.64 Million
Observe Medical Asa (OBSRV)	$16.82 Million	13.52%	2.50x	$16.19 Million

About Gentian Diagnostics AS

OL:GENT Norway Medical Devices

Market Cap

$72.38 Million

Nkr687.84 Million NOK

Market Cap Rank

#20446 Global

#181 in Norway

Share Price

Nkr44.60

Change (1 day)

+9.85%

52-Week Range

Nkr37.60 - Nkr64.80

All Time High

Nkr86.00